Astellas Pharma (OTCMKTS:ALPMY) Sees Large Volume Increase – Here’s Why

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw strong trading volume on Monday . 133,468 shares traded hands during trading, a decline of 15% from the previous session’s volume of 157,048 shares.The stock last traded at $15.07 and had previously closed at $15.18.

Wall Street Analyst Weigh In

Separately, Zacks Research downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Astellas Pharma has an average rating of “Moderate Buy”.

Astellas Pharma Trading Down 0.3%

The firm has a market cap of $27.38 billion, a price-to-earnings ratio of 11.51 and a beta of 0.08. The business has a 50 day moving average of $14.36 and a 200 day moving average of $14.53. The company has a quick ratio of 0.93, a current ratio of 1.20 and a debt-to-equity ratio of 0.16.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops and commercializes prescription medicines for serious and unmet medical needs. Its research and commercial activities focus on areas including oncology, urology, immunology, neuromuscular diseases, ophthalmology and other specialty conditions.

The company’s portfolio includes treatments such as XTANDI for certain prostate cancers, XOSPATA for acute myeloid leukemia, MYRBETRIQ for overactive bladder and VEOZAH for menopausal hot flashes.